DNA X, Inc.·4

Feb 10, 8:53 PM ET

MULICA MICHAEL C 4

Research Summary

AI-generated summary

Updated

DNA X (SONM) Acting CEO Michael Mulica Receives Award

What Happened
Michael C. Mulica, Acting CEO and a director of DNA X, Inc. (SONM), received a grant of 50,000 restricted stock units (RSUs) on February 9, 2026. The RSUs were granted at an acquisition price of $0 and represent the contingent right to receive one share of common stock per RSU when vested. This was an award (compensation), not an open-market purchase or sale; total immediate cash value reported is $0.

Key Details

  • Transaction date: 2026-02-09; Form 4 filed 2026-02-10 (timely filing).
  • Transaction type/code: Award/Grant (A). Price reported: $0.00.
  • Shares reported after transaction: consists of 4,071 shares of common stock and 50,000 unvested RSUs (per filing footnote).
  • Vesting: RSUs vest in equal monthly installments over one year, subject to Mulica’s continued service (footnote F1).
  • Reverse split: Reported security counts reflect a 1-for-18 reverse stock split effective Oct 27, 2025 (footnote F3).
  • No sale, cashless exercise, or tax-withholding event reported in this Form 4.

Context
RSUs are a form of equity compensation that convert into actual shares as they vest; because these RSUs vest over time and were granted at $0, they are compensation rather than a market buy signal. Awards like this are common for executive compensation and do not necessarily indicate immediate buying or selling activity by the insider.